Viewing Study NCT07130032

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 9:30 PM
Ignite Modification Date: 2026-01-02 @ 12:58 PM
Study NCT ID: NCT07130032
Status: RECRUITING
Last Update Posted: 2025-08-19
First Post: 2025-08-14
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: Efficacy And Safety Of Anti-PD-1/PD-L1 Antibodies In Combination With Bevacizumab And Metronomic Cyclophosphamide In Patients With Non-Small Cell Lung Cancer And Cutaneous Melanoma Previously Treated With Immune Checkpoint Blockade
Sponsor: EuroCityClinic LLC
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Metastatic Non-small Cell Lung Cancer (NSCLC) View
None Metastatic Cutaneous Melanoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Metastatic non-small cell lung cancer View
None Metastatic cutaneous melanoma View
None Immune checkpoint inhibitor View
None Bevacizumab View
None Metronomic cyclophosphamide View